ArticleDigestive diseases and sciences2026
Real World Performance of the Model for End-Stage Liver Disease Score Across Different Races and Ethnicities.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MELD and the Risk of Mortality Between Black and White Patients with Advanced Fibrosis.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsThe MELD score assesses liver disease severity and guides liver allocation in the United States. This study aims to address the knowledge gap regarding potential disparities in the performance of MELD-Na and MELD 3.0 scores across races and ethnicities.
methodsA retrospective cohort study of Asian, White, African American, and Hispanic patients with cirrhosis from MIMIC-IV (Beth Israel Deaconess Medical Center) and Emory University databases. The performance of the MELD scores in predicting a composite outcome of death or liver transplant (LT) during the hospital stay or within 90 days was analyzed using AUROC for discrimination, and calibration curves for calibration.
resultsA total of 4,306 patients with cirrhosis from MIMIC-IV and 5801 patients from Emory were included. Across both datasets, no significant differences were found in the discriminative ability of both scores to predict in-hospital death or LT across races and ethnicities (p > 0.05). A small group of Asian patients influenced score performance differences at 90 days in MIMIC-IV. Calibration plots showed both scores tend to overpredict outcomes at higher values, particularly MELD-Na in MIMIC-IV among African Americans.
conclusionsBoth scores demonstrated consistent discriminative ability across major ethnic/racial groups. Both scores predicted outcomes better in Emory, a high-volume LT center, than in MIMIC-IV, suggesting site-specific differences and the Emory cohort's closer resemblance to populations used for MELD derivation. These findings suggest disparities in cirrhosis care may relate to socioeconomic factors rather than score performance.
Indexed as
Identifiers
40900363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.